This CME/CE activity will highlight recent data for the treatment and management of multiple myeloma (MM), including information presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. The expert faculty, chaired by C. Ola Landgren, MD, PhD, will first discuss the pathophysiology of multiple myeloma, reviewing the skeletal, renal, hematologic and neurologic processes in a case-based format. Current clinical trial data of approved therapeutic options as well as emerging agents will be reviewed, and clinical relevance debated. The faculty will cover best practices for improving quality of life and adherence to therapy through personalized medicine utilizing the interprofessional team. This CME/CE activity will update healthcare professionals on best practices for providing optimal, comprehensive care in multiple myeloma.
Oncologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with multiple myeloma
1. Discuss the skeletal, renal, hematologic, and neurologic processes to understand the pathophysiology of multiple myeloma
2. Analyze clinical data of new pharmacologic treatments to improve quality of life in patients with multiple myeloma, including data presented at ASCO 2019
3. Create effective treatment regimens with the healthcare team to achieve optimal outcomes and manage patients with multiple myeloma
Beth Faiman, PhD, MSN, APN-BC, AOCN
Department of Hematologic Oncology
Cleveland Clinic Taussig Cancer Institute
Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma and Amyloidosis Program
Division of Hematology/Oncology
Herbert Irving Comprehensive Cancer Center
New York Presbyterian Hospital/ Columbia University Medical Center
Professor of Clinical Medicine
New York, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|C. Ola Landgren, MD, PhD (Course Chair)
|Consultant/Advisor: Janssen Pharmaceuticals, Inc.; Merck & Co.; Takeda Pharmaceutical Company
Grant/Research Support: Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Takeda Pharmaceutical Company
Speaker’s Bureau: Amgen Inc.; Bristol Myers-Squibb Company; Celgene Corporation; Janssen Pharmaceuticals, Inc.
|Beth Faiman, PhD, MSN, APN-BC, AOCN
|Consultant/Advisor: Amgen Inc.; Bristol Myers-Squibb Company; Celgene Corporation; Takeda Pharmaceutical Company|
Suzanne Lentzsch, MD, PhD
|Consultant/Advisor: AbbVie Inc.; Bayer AG; Caelum Biosciences, Inc.; Proclara Biosciences; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company
Grant/Research Support: Karyopharm Therapeutics; Sanofi
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this live material for a maximum of 1.0 CNE contact hour, including 1.0 pharmacotherapeutic contact hour (Provider number P0491).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Amgen Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME inquiries or special needs, please contact [email protected].